Insulin-like growth factor binding protein-1 at the maternal-fetal interface and insulin-like growth factor-I, insulin-like growth factor-II, and insulin-like growth factor binding protein-1 in the circulation of women with severe preeclampsia

• Published in: American journal of obstetrics and gynecology Vol. 176; no. 4; pp. 751 - 758
• Main Authors: Giudice, Linda C., Martina, Natalie A., Crystal, Ruth Ann, Tazuke, Salli, Druzin, Maurice
• Format: Journal Article
• Language: English
• Published: United States Mosby, Inc 01.04.1997
• Subjects: Adolescent; Adult; Case-Control Studies; Decidua - chemistry; Female; Humans; Insulin-like growth factor; insulin-like growth factor binding protein; Insulin-Like Growth Factor Binding Protein 1 - analysis; Insulin-Like Growth Factor Binding Protein 1 - blood; Insulin-Like Growth Factor I - analysis; Insulin-Like Growth Factor II - analysis; Obstetric Labor, Premature - blood; Obstetric Labor, Premature - pathology; Pre-Eclampsia - blood; Pre-Eclampsia - pathology; preeclampsia; Pregnancy - blood; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Trophoblasts - chemistry; Insulin-like growth factor; preeclampsia; insulin-like growth factor binding protein
• ISSN: 0002-9378
• DOI: 10.1016/S0002-9378(97)70598-2

OBJECTIVES: Preeclampsia is characterized by maternal hypertension, proteinuria, edema, and shallow placental invasion. Insulin-like growth factor binding protein-1, abundant in maternal decidua, is believed to play a role in limiting trophoblast invasiveness. In this study we addressed the hypothesis that this binding protein is aberrantly expressed in preeclampsia. We also investigated circulating levels of insulin-like growth factor-I and insulin-like growth factor-II in subjects with severe preeclampsia compared with controls. STUDY DESIGN: Insulin-like growth factor binding protein-1 was investigated by immunohistochemistry at the maternal-fetal interface of eight pregnancies complicated by severe preeclampsia and six controls between 21 and 34 weeks of gestation. Cell types were identified with use of cell-specific markers. Circulating levels of insulin-like growth factor binding protein-1, insulin-like growth factor-I, and insulin-like growth factor-II in 16 patients with severe preeclampsia and 29 controls at the same gestational age were determined by an immunoradiometric assay and correlated with clinical parameters. Data were analyzed by t test and Pearson's method. RESULTS: Insulin-like growth factor binding protein-1 was highly expressed on syncytiotrophoblasts, cytotrophoblasts, and decidual cells but not on placental fibroblasts. Immunostaining was greater at the maternal-fetal interface in severe preeclamptic patients compared with controls. Circulating insulin-like growth factor binding protein-1 levels in subjects with severe preeclampsia were 428.3 ± 85.9 ng/ml compared with 76.6 ± 11.8 in controls ( p = 0.0007). Circulating insulin-like growth factor-I levels were 80.9 ± 17.2 ng/ml compared with 179.4 ± 28.2 ng/ml in controls ( p = 0.0001). In contrast, insulin-like growth factor-II levels were not significantly different in the two groups. In subjects with severe preeclampsia insulin-like growth factor binding protein-1 levels correlated with diastolic blood pressure ( r = 0.498, p = 0.049) and aspartate transcarbamylase (0.621, p = 0.010). CONCLUSIONS: The abundance of insulin-like growth factor binding protein-1 at the maternal-fetal interface in severely preeclamptic pregnancies suggests that the binding protein may participate in the pathogenesis of the shallow placental invasion observed in this disorder. Low circulating insulin-like growth factor-I and elevated insulin-like growth factor binding protein-1 levels may contribute to restricted placental and therefore fetal growth. (Am J Obstet Gynecol 1997;176:751-8.)